Mar 18,2024

Researchers Develop Deep Learning Model to Predict Breast Cancer

A new study published in Radiology reveals the development of an interpretable artificial intelligence (AI) model, named AsymMirai, for predicting 5-year breast cancer risk from mammograms. Traditional mammography screening can significantly lower the risk of breast cancer-related mortality, but accurately predicting which women will develop breast cancer remains challenging. While previous AI models, such as Mirai, have shown promise in this regard, their complex reasoning process raises concerns about overreliance and potential misdiagnoses. Lead author Jon Donnelly and colleagues at Duke University developed AsymMirai, a simplified AI method that enhances interpretability compared to Mirai. By analyzing 210,067 mammograms from 81,824 patients, the researchers demonstrated that AsymMirai performs almost as well as Mirai in predicting 1- to 5-year breast cancer risk. AsymMirai's straightforward reasoning process makes it a valuable tool for assisting radiologists in breast cancer diagnosis and risk prediction.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 21,2024

New Research Shows Long-Term A1C Reduction and Sustained Weight Maintenance in Omada Health’s Type 2 Diabetes Program

Omada Health recently published its 28th peer-reviewed study demonstrating the long-term outcomes of utilizing a behavior change program for members with T2D. The study, published in The Science of Diabetes Self-Management and Care,  come on the heels of the company’s Insights Lab expansion, which established the ANSWERS initiative to focus on insights derived from combining GLP-1s with a proven behavior change approach. Researchers analyzed data from more than 1,000 commercially insured members with T2D who were enrolled between January 1, 2019, and January 31, 2022, in Omada’s virtual care solution. Within this group, changes in A1C levels and weight were examined over 12 months. Key results show that members with elevated A1C (over or equal to 8%) at baseline experienced an average 1.8-point decline in A1C over 12 months. Also, members collectively experienced an average reduction of 7.3 pounds over 12 months.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 20,2024

AI-Based App can Help Physicians Find Skin Melanoma

A study led by Linköping University in Sweden tested a mobile app, Dermalyser (AI Medical Technology, Stockholm, Sweden), using artificial intelligence (AI) to analyze images of skin lesions for diagnosing melanoma in primary care settings. Published in the British Journal of Dermatology, the study revealed promising results, showing the app's high precision in identifying melanoma and distinguishing it from harmless lesions. The app detected all melanomas and missed only one precursor, with a 99.5% probability of accurately identifying non-melanoma lesions. While the app's effectiveness is encouraging, further research is needed to evaluate its real-world utility as a decision support tool. The researchers plan to conduct a larger follow-up study in multiple countries to assess the app's performance in active decision-making scenarios.

CLINICAL STUDY

#mobile app

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 14,2024 TOP STORY

Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment

Lunit announced the publication of a new study featuring Lunit SCOPE HER2 and Lunit SCOPE ER/PR, Lunit's AI-powered analyzer of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR). The study aimed to evaluate the role of Lunit SCOPE in enhancing pathologists’ consistency and accuracy of breast cancer molecular subtype classification. Results from the study demonstrated a significant increase in agreement among pathologists on the status of HER2, ER, and PR, especially in cases with intermediate weakly positive expressions. Notably, AI assistance led to an increase in agreement on HER2 status from 49.3% to 74.1%, ER from 93.0% to 96.5%, and PR from 84.6% to 91.5%. Consequently, with AI assistance, the agreement among pathologists in classification of breast cancer molecular subtypes saw an increase from 58.2% to 78.6%.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 06,2024 TOP STORY

REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRE® SYSTEMS AND GLP-1 MEDICINES WORK BETTER TOGETHER FOR PEOPLE WITH TYPE 2 DIABETES

Abbott announced new data showing that individuals with Type 2 diabetes using GLP-1 medicines alongside FreeStyle Libre technology experienced greater improvement in their HbA1c levels compared to those using GLP-1 medicines alone. GLP-1 medicines stimulate insulin release and aid weight loss in Type 2 diabetes management. The studies presented at ATTD revealed significant HbA1c improvements (-1.5% to -2.4%) after adding FreeStyle Libre technology to GLP-1 therapy, regardless of GLP-1 duration or insulin therapy. This combination enhances glycemic control and supports positive behavior changes by providing real-time glucose data.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 09,2024 TOP STORY

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

Medtronic plc. shared new real-world data on the MiniMed™ 780G system at the ATTD conference in Florence, Italy, indicating its strong global performance in managing type 1 diabetes. The data showed that over 100,000 users achieved a Time in Range (TIR) of 78%, surpassing international targets. Additionally, the system helped users achieve Time in Tight Range (TITR) goals, with over 56% of users spending time in the 70-140 mg/dL glucose range. Early U.S. users of the system achieved over 80% TIR, surpassing international glycemic targets recommended by the ADA. The system also received high satisfaction ratings and improved quality of life benefits. These findings underscore the system's effectiveness in managing diabetes and advancing patient care.

CLINICAL STUDY

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

DarioHealth presented two new clinical studies at the ATTD 2024 conference in Italy. The first study explored the impact of Dario's integrated solution for weight and diabetes management, with or without GLP-1 medications. It showed a 6.38% weight reduction among pre-diabetic users over a year, along with decreased blood glucose levels, particularly for those consistently engaged in meal tracking. The second study focused on improving flu vaccine awareness among Dario members with Type 1 or Type 2 diabetes. Results revealed that those receiving intervention messages showed higher self-reported vaccination rates compared to those who didn't. Members receiving more frequent messages reported even higher vaccination rates and greater awareness of flu risks.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024 TOP STORY

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

DarioHealth presented two new clinical studies at the ATTD 2024 conference in Italy. The first study explored the impact of Dario's integrated solution for weight and diabetes management, with or without GLP-1 medications. It showed a 6.38% weight reduction among pre-diabetic users over a year, along with decreased blood glucose levels, particularly for those consistently engaged in meal tracking. The second study focused on improving flu vaccine awareness among Dario members with Type 1 or Type 2 diabetes. Results revealed that those receiving intervention messages showed higher self-reported vaccination rates compared to those who didn't. Members receiving more frequent messages reported even higher vaccination rates and greater awareness of flu risks.

CLINICAL STUDY

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Mar 05,2024 TOP STORY

The DTx Solution for Borderline Personality Disorder, priovi Secures Permanent Reimbursement in Germany with the Phase 3 Trial Results

priovi, the world’s first and only fully automated digital therapy for borderline personality disorder (BPD) developed by GAIA Group, has been available for clinical use in Germany since March 2023, and now its effectiveness has been confirmed in a large clinical trial (RCT) with 580 patients. Thanks to the positive results, the Federal Institute for Drugs and Medical Devices (BfArM) in Germany granted permanent reimbursement for priovi's digital therapy intervention. The study, which included 580 patients, showed a significant and clinically relevant reduction in borderline symptoms as well as a decrease in both depression and anxiety symptoms in the intervention group, compared to the control group. In addition, the number of suicide attempts was significantly lower in the priovi group. Patients also reported a high level of satisfaction while using the program and their satisfaction scores increased with time.

CLINICAL STUDY

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Mar 08,2024

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Insulet Corporation presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System. The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes in Florence, Italy. Insulet presented data for 194 adults who had used traditional (non-AID) insulin pump therapy (including 87% using the Omnipod or Omnipod DASH® Insulin Management System) for three months or longer and had a HbA1c between 7 and 11% (mean 8.5%). The participants had type 1 diabetes for at least one year and were enrolled at 14 institutions across the United States (61%) and France (39%). The participants were randomized into two groups and studied over the course of 13 weeks. The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6. According to the results presented, the participants using Omnipod 5 showed a significantly greater TIR by 17.5% (43.8% in Control group versus 61.2% in Intervention group), or an additional 4.2 hours per day, and a greater reduction in HbA1c by 0.58% (1.24% with Omnipod 5 vs. 0.68% in the Control group). The final HbA1c was 7.25% in the Omnipod 5 group versus 7.84% in the Control group.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY